For: |
Wang HH, Chou JW, Liao KF, Lin ZY, Lai HC, Hsu CH, Chen CB. One-year follow-up study of |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v11/i11/1680.htm |
Number | Citing Articles |
1 |
E. G. GIANNINI, C. BILARDI, P. DULBECCO, M. MAMONE, M. L. SANTI, R. TESTA, C. MANSI, V. SAVARINO. A study of 4‐ and 7‐day triple therapy with rabeprazole, high‐dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2006; 23(2): 281 doi: 10.1111/j.1365-2036.2006.02756.x
|
2 |
Chii-Shyan Lay, Jiun-Rong Lin. Correlation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer. Journal of the Chinese Medical Association 2010; 73(4): 188 doi: 10.1016/S1726-4901(10)70039-3
|
3 |
Meng‐Kwan Liu, I‐Chen Wu, Chien‐Yu Lu, Chao‐Hung Kuo, Fang‐Jung Yu, Chung‐Jung Liu, Ping‐I Hsu, Wen‐Hung Hsu, Yu‐Chung Su, Angela Chen, Deng‐Chyang Wu, Fu‐Chen Kuo, Jyh‐Jou Chen. Randomized trial comparing rabeprazole‐ versus lansoprazole‐based Helicobacter pylori eradication regimens. The Kaohsiung Journal of Medical Sciences 2013; 29(7): 379 doi: 10.1016/j.kjms.2012.11.006
|
4 |
Ala I Sharara. Rabeprazole: the role of proton pump inhibitors inHelicobacter pylorieradication. Expert Review of Anti-infective Therapy 2005; 3(6): 863 doi: 10.1586/14787210.3.6.863
|
5 |
Edoardo G. Giannini, Claudio Bilardi, Pietro Dulbecco, Mario Mamone, Maria L. Santi, Roberto Testa, Carlo Mansi, Vincenzo Savarino. Can Helicobacter pylori Eradication Regimens be Shortened in Clinical Practice? An Open-label, Randomized, Pilot Study of 4 and 7-day Triple Therapy With Rabeprazole, High-dose Levofloxacin, and Tinidazole. Journal of Clinical Gastroenterology 2006; 40(6): 515 doi: 10.1097/00004836-200607000-00010
|